Literature DB >> 7958539

LDL subclasses in IDDM patients: relation to diabetic nephropathy.

S Lahdenperä1, P H Groop, M Tilly-Kiesi, T Kuusi, T G Elliott, G C Viberti, M R Taskinen.   

Abstract

To answer the question whether the elevation of LDL-cholesterol in IDDM patients with incipient and established diabetic nephropathy is accompanied by changes in LDL size or composition, we studied distribution of LDL particles in 57 normoalbuminuric [AER 7 (1-9) micrograms/min, median and range], in 46 microalbuminuric [AER 50 (20-192) micrograms/min] and in 33 proteinuric [AER 422 (233-1756) micrograms/min] IDDM patients as well as in 49 non-diabetic control subjects with normoalbuminuria. The three diabetic groups were matched for duration of diabetes and glycaemic control. The mean particle diameter of the major LDL peak was determined by nondenaturing gradient gel electrophoresis. Composition and density distribution of LDL were determined in the subgroups of each patient group by density gradient ultracentrifugation. Normoalbuminuric IDDM patients had larger LDL particles than non-diabetic control subjects (260 A vs 254 A, p < 0.05). LDL particle diameter was inversely correlated with serum triglycerides in all groups (p < 0.05 for normoalbuminuric and p < 0.001 for other groups). Triglyceride content of LDL was higher in three IDDM groups compared to control group (p < 0.05). The elevation of LDL mass in microalbuminuric and proteinuric IDDM groups compared to normoalbuminuric IDDM group (p < 0.05 for both) was mainly due to the increment of light LDL (density 1.0212-1.0343 g/ml). There were no significant changes in the density distribution or composition of LDL between the three diabetic groups. In conclusion the increase of LDL mass without major compositional changes suggests that the elevation of LDL in incipient and established diabetic nephropathy is primarily due to the increased number of LDL particles.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7958539     DOI: 10.1007/BF00417692

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  49 in total

1.  Effect of exercise and menstrual cycle status on plasma lipids, low density lipoprotein particle size, and apolipoproteins.

Authors:  S Lamon-Fava; E C Fisher; M E Nelson; W J Evans; J S Millar; J M Ordovas; E J Schaefer
Journal:  J Clin Endocrinol Metab       Date:  1989-01       Impact factor: 5.958

2.  Nondenaturing polyacrylamide gradient gel electrophoresis.

Authors:  A V Nichols; R M Krauss; T A Musliner
Journal:  Methods Enzymol       Date:  1986       Impact factor: 1.600

3.  Susceptibility of small, dense, low-density lipoproteins to oxidative modification in subjects with the atherogenic lipoprotein phenotype, pattern B.

Authors:  A Chait; R L Brazg; D L Tribble; R M Krauss
Journal:  Am J Med       Date:  1993-04       Impact factor: 4.965

4.  The effect of proteinuria on relative mortality in type 1 (insulin-dependent) diabetes mellitus.

Authors:  K Borch-Johnsen; P K Andersen; T Deckert
Journal:  Diabetologia       Date:  1985-08       Impact factor: 10.122

5.  Surface binding, internalization and degradation by cultured human fibroblasts of low density lipoproteins isolated from type 1 (insulin-dependent) diabetic patients: changes with metabolic control.

Authors:  M F Lopes-Virella; G K Sherer; A M Lees; H Wohltmann; R Mayfield; J Sagel; E C LeRoy; J A Colwell
Journal:  Diabetologia       Date:  1982-06       Impact factor: 10.122

6.  Increased cholesterylester transfer activity in complicated type 1 (insulin-dependent) diabetes mellitus--its relationship with serum lipids.

Authors:  R P Dullaart; J E Groener; L D Dikkeschei; D W Erkelens; H Doorenbos
Journal:  Diabetologia       Date:  1989-01       Impact factor: 10.122

7.  Low-density lipoprotein metabolism in the nephrotic syndrome.

Authors:  G L Warwick; M J Caslake; J M Boulton-Jones; M Dagen; C J Packard; J Shepherd
Journal:  Metabolism       Date:  1990-02       Impact factor: 8.694

8.  Low-density lipoprotein subclass patterns and risk of myocardial infarction.

Authors:  M A Austin; J L Breslow; C H Hennekens; J E Buring; W C Willett; R M Krauss
Journal:  JAMA       Date:  1988-10-07       Impact factor: 56.272

9.  The effect of lovastatin treatment on low-density lipoprotein hydrated density distribution and composition in patients with intermittent claudication and primary hypercholesterolemia.

Authors:  M Tilly-Kiesi
Journal:  Metabolism       Date:  1991-06       Impact factor: 8.694

10.  Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.

Authors:  S L Jones; C F Close; M B Mattock; R J Jarrett; H Keen; G C Viberti
Journal:  BMJ       Date:  1989-02-25
View more
  5 in total

Review 1.  Is it possible to predict diabetic kidney disease?

Authors:  S M Thomas; G C Viberti
Journal:  J Endocrinol Invest       Date:  2000-01       Impact factor: 4.256

2.  Increased small dense LDL and intermediate-density lipoprotein with albuminuria in type 1 diabetes.

Authors:  S D Sibley; J E Hokanson; M W Steffes; J Q Purnell; S M Marcovina; P A Cleary; J D Brunzell
Journal:  Diabetes Care       Date:  1999-07       Impact factor: 19.112

Review 3.  Cost-effective strategies in the prevention of diabetic nephropathy.

Authors:  Jonathan D Rippin; Anthony H Barnett; Stephen C Bain
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

4.  Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in Type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study.

Authors:  S S Soedamah-Muthu; Y-F Chang; J Otvos; R W Evans; T J Orchard
Journal:  Diabetologia       Date:  2003-05-13       Impact factor: 10.122

5.  Lower levels of total HDL and HDL3 cholesterol are associated with albuminuria in normoalbuminuric Type 1 diabetic patients.

Authors:  T Bulum; B Kolaric; L Duvnjak
Journal:  J Endocrinol Invest       Date:  2013-02-12       Impact factor: 4.256

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.